Femara 2.5mg is a prescription medicine from Novartis containing letrozole, a nonsteroidal aromatase inhibitor. Each film-coated tablet provides 2.5mg of letrozole. The medicine is prescribed for selected hormone receptor-positive breast cancer conditions in postmenopausal women, under specialist supervision. This presentation contains 30 tablets in blister packaging.
Femara 2.5mg must be taken exactly as prescribed by the specialist. The usual recommended adult dose is one 2.5mg tablet once daily, although individual instructions must always take priority. Tablets may be taken with or without food and should be swallowed with water. Taking the medicine at a consistent time can support adherence to the prescribed schedule. Do not adjust the dose, interrupt therapy or discontinue the medicine without medical advice. If a dose is missed, follow the patient leaflet or contact the healthcare team rather than taking an additional dose without guidance. Femara must not be used during pregnancy or breastfeeding. Bone health and other relevant clinical parameters may require monitoring during therapy. Report unusual symptoms or suspected adverse reactions to the prescribing team.
Letrozole inhibits the aromatase enzyme, which is involved in the production of oestrogen from androgen hormones. In postmenopausal women, this process represents an important source of circulating oestrogen. Reducing oestrogen production supports medical management of selected hormone-sensitive breast cancer conditions. The medicine works through a systemic hormonal mechanism and requires an individualised specialist care plan. Its use is based on the patient's diagnosis, menopausal status and clinical assessment.
Each film-coated tablet contains 2.5mg letrozole. Additional ingredients include lactose monohydrate, microcrystalline cellulose, maize starch, sodium starch glycolate, magnesium stearate and colloidal anhydrous silica. The coating contains hypromellose, talc, macrogol 8000, titanium dioxide and yellow iron oxide. The formulation contains lactose.
Femara 2.5mg provides a defined letrozole strength for specialist-supervised hormonal care. Its oral tablet format supports a structured prescription schedule within an individual medical management plan.
Femara is a Novartis medicine associated with manufacturing facilities in Switzerland and Italy. The specific manufacturing country should be confirmed from the supplied pack. Store below 30°C in the original packaging, protected from moisture and out of children's reach. It is available at Pharmacy Plus Kuwait.